These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26376779)

  • 21. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rosiglitazone and cardiovascular risk.
    Kaul S; Diamond GA
    Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC
    J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
    Habib ZA; Tzogias L; Havstad SL; Wells K; Divine G; Lanfear DE; Tang J; Krajenta R; Pladevall M; Williams LK
    Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):437-47. PubMed ID: 19235778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias Tool.
    Bilandzic A; Fitzpatrick T; Rosella L; Henry D
    PLoS Med; 2016 Apr; 13(4):e1001987. PubMed ID: 27046153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.
    Chen X; Yang L; Zhai SD
    Chin Med J (Engl); 2012 Dec; 125(23):4301-6. PubMed ID: 23217404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.
    Hall GC; Smith HT; Curtis B; McMahon AD
    Int J Clin Pract; 2011 May; 65(5):586-91. PubMed ID: 21489082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.
    Ruiter R; Visser LE; van Herk-Sukel MP; Geelhoed-Duijvestijn PH; de Bie S; Straus SM; Mol PG; Romio SA; Herings RM; Stricker BH
    Drug Saf; 2012 Jun; 35(6):471-80. PubMed ID: 22540371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term risk of rosiglitazone on cardiovascular events - a systematic review and meta-analysis.
    Cheng D; Gao H; Li W
    Endokrynol Pol; 2018; 69(4):381-394. PubMed ID: 29952413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
    Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
    J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.
    Motola D; Piccinni C; Biagi C; Raschi E; Marra A; Marchesini G; Poluzzi E
    Drug Saf; 2012 Apr; 35(4):315-23. PubMed ID: 22376166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
    Mahaffey KW; Hafley G; Dickerson S; Burns S; Tourt-Uhlig S; White J; Newby LK; Komajda M; McMurray J; Bigelow R; Home PD; Lopes RD
    Am Heart J; 2013 Aug; 166(2):240-249.e1. PubMed ID: 23895806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
    Wallach JD; Wang K; Zhang AD; Cheng D; Grossetta Nardini HK; Lin H; Bracken MB; Desai M; Krumholz HM; Ross JS
    BMJ; 2020 Feb; 368():l7078. PubMed ID: 32024657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.
    Hernandez AV; Walker E; Ioannidis JP; Kattan MW
    Am Heart J; 2008 Jul; 156(1):23-30. PubMed ID: 18585493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Lamanna C; Gensini GF; Marchionni N
    Diabetes Obes Metab; 2008 Dec; 10(12):1221-38. PubMed ID: 18505403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.
    Jain R; Mullins CD; Lee H; Wong W
    Res Social Adm Pharm; 2012; 8(1):47-59. PubMed ID: 21733760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan.
    Hsu JC; Cheng CL; Ross-Degnan D; Wagner AK; Zhang F; Kao Yang YH; Liu LL; Tai HY; Chen KH; Yang PW; Lu CY
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1026-35. PubMed ID: 26251229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
    Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
    N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.